A Complex Interplay Between Akt, TSC2 and the Two MTOR Complexes

Overview

Journal Biochem Soc Trans

Specialty Biochemistry

Date 2009 Jan 16

PMID 19143635

Citations 359

Authors

Jingxiang Huang

Brendan D Manning

Affiliations

Soon will be listed here.

Abstract

Akt/PKB (protein kinase B) both regulates and is regulated by the TSC (tuberous sclerosis complex) 1-TSC2 complex. Downstream of PI3K (phosphoinositide 3-kinase), Akt phosphorylates TSC2 directly on multiple sites. Although the molecular mechanism is not well understood, these phosphorylation events relieve the inhibitory effects of the TSC1-TSC2 complex on Rheb and mTORC1 [mTOR (mammalian target of rapamycin) complex] 1, thereby activating mTORC1 in response to growth factors. Through negative-feedback mechanisms, mTORC1 activity inhibits growth factor stimulation of PI3K. This is particularly evident in cells and tumours lacking the TSC1-TSC2 complex, where Akt signalling is severely attenuated due, at least in part, to constitutive activation of mTORC1. An additional level of complexity in the relationship between Akt and the TSC1-TSC2 complex has recently been uncovered. The growth-factor-stimulated kinase activity of mTORC2 [also known as the mTOR-rictor (rapamycin-insensitive companion of mTOR) complex], which normally enhances Akt signalling by phosphorylating its hydrophobic motif (Ser(473)), was found to be defective in cells lacking the TSC1-TSC2 complex. This effect on mTORC2 can be separated from the inhibitory effects of the TSC1-TSC2 complex on Rheb and mTORC1. The present review discusses our current understanding of the increasingly complex functional interactions between Akt, the TSC1-TSC2 complex and mTOR, which are fundamentally important players in a large variety of human diseases.

Citing Articles

TP53 Codon 72 Polymorphism Impacts Macrophage Activation through Reactive Oxygen Species-Dependent Cell Signaling Alterations.

Silwal A, Reese B, Patel B, Li Y, Kolev M, La-Beck N J Immunol. 2024; 213(12):1844-1857.

PMID: 39451031 PMC: 11611636. DOI: 10.4049/jimmunol.2400212.

Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?.

Ouissam A, Hind C, Sami Aziz B, Said A Ther Adv Med Oncol. 2024; 16:17588359241284911.

PMID: 39399412 PMC: 11468005. DOI: 10.1177/17588359241284911.

Metformin and the PI3K/AKT signaling pathway: implications for cancer, cardiovascular, and central nervous system diseases.

Ashayeri Ahmadabad H, Mohammadi Panah S, Ghasemnejad-Berenji H, Ghojavand S, Ghasemnejad-Berenji M, Khezri M Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(2):1035-1055.

PMID: 39225830 DOI: 10.1007/s00210-024-03358-3.

Role and mechanisms of autophagy, ferroptosis, and pyroptosis in sepsis-induced acute lung injury.

Shen Y, He Y, Pan Y, Liu L, Liu Y, Jia J Front Pharmacol. 2024; 15:1415145.

PMID: 39161900 PMC: 11330786. DOI: 10.3389/fphar.2024.1415145.

A Comprehensive Review of HER2 in Cancer Biology and Therapeutics.

Cheng X Genes (Basel). 2024; 15(7).

PMID: 39062682 PMC: 11275319. DOI: 10.3390/genes15070903.

References

Fingar D, Blenis J . Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 2004; 23(18):3151-71. DOI: 10.1038/sj.onc.1207542. View

Manning B . Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol. 2004; 167(3):399-403. PMC: 2172491. DOI: 10.1083/jcb.200408161. View

Ikenoue T, Inoki K, Yang Q, Zhou X, Guan K . Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J. 2008; 27(14):1919-31. PMC: 2486275. DOI: 10.1038/emboj.2008.119. View

Zhang H, Lipovsky A, Dibble C, Sahin M, Manning B . S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell. 2006; 24(2):185-97. PMC: 1880887. DOI: 10.1016/j.molcel.2006.09.019. View

Harrington L, Findlay G, Gray A, Tolkacheva T, Wigfield S, Rebholz H . The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol. 2004; 166(2):213-23. PMC: 2172316. DOI: 10.1083/jcb.200403069. View

Frias M, Thoreen C, Jaffe J, Schroder W, Sculley T, Carr S . mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol. 2006; 16(18):1865-70. DOI: 10.1016/j.cub.2006.08.001. View

Huang J, Dibble C, Matsuzaki M, Manning B . The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol. 2008; 28(12):4104-15. PMC: 2423120. DOI: 10.1128/MCB.00289-08. View

Kwiatkowski D, Zhang H, Bandura J, Heiberger K, Glogauer M, El-Hashemite N . A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet. 2002; 11(5):525-34. DOI: 10.1093/hmg/11.5.525. View

Inoki K, Li Y, Zhu T, Wu J, Guan K . TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002; 4(9):648-57. DOI: 10.1038/ncb839. View

10.

Alessi D, James S, Downes C, Holmes A, Gaffney P, Reese C . Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 1997; 7(4):261-9. DOI: 10.1016/s0960-9822(06)00122-9. View

11.

Alessi D, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P . Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996; 15(23):6541-51. PMC: 452479. View

12.

Crino P, Nathanson K, Henske E . The tuberous sclerosis complex. N Engl J Med. 2006; 355(13):1345-56. DOI: 10.1056/NEJMra055323. View

13.

Sarbassov D, Guertin D, Ali S, Sabatini D . Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005; 307(5712):1098-101. DOI: 10.1126/science.1106148. View

14.

Manning B, Tee A, Logsdon M, Blenis J, Cantley L . Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell. 2002; 10(1):151-62. DOI: 10.1016/s1097-2765(02)00568-3. View

15.

Manning B, Cantley L . Rheb fills a GAP between TSC and TOR. Trends Biochem Sci. 2003; 28(11):573-6. DOI: 10.1016/j.tibs.2003.09.003. View

16.

Cai S, Tee A, Short J, Bergeron J, Kim J, Shen J . Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol. 2006; 173(2):279-89. PMC: 2063818. DOI: 10.1083/jcb.200507119. View

17.

Harvey K, Mattila J, Sofer A, Bennett F, Ramsey M, Ellisen L . FOXO-regulated transcription restricts overgrowth of Tsc mutant organs. J Cell Biol. 2008; 180(4):691-6. PMC: 2265581. DOI: 10.1083/jcb.200710100. View

18.

Guertin D, Stevens D, Thoreen C, Burds A, Kalaany N, Moffat J . Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell. 2006; 11(6):859-71. DOI: 10.1016/j.devcel.2006.10.007. View

19.

Toker A, Newton A . Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J Biol Chem. 2000; 275(12):8271-4. DOI: 10.1074/jbc.275.12.8271. View

20.

Harrington L, Findlay G, Lamb R . Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci. 2005; 30(1):35-42. DOI: 10.1016/j.tibs.2004.11.003. View